Cedar Mountain Advisors’s Pacira BioSciences PCRX Stock Holding History

Cedar Mountain Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$355	Hold	14	–	–	﹤0.01%	1084
2026 Q1	$316	Buy	+14	New	+$311	﹤0.01%	1069

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cedar Mountain Advisors's PCRX Position: Q2 2026 in Review

Cedar Mountain Advisors held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 14 shares worth $355. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Cedar Mountain Advisors first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Cedar Mountain Advisors held 14 shares of Pacira BioSciences worth $355 as of Q2 2026.
Cedar Mountain Advisors left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #1084 holding.
Cedar Mountain Advisors first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.